1. Home
  2. RNXT

as 10-29-2025 9:37am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Founded: 2012 Country:
United States
United States
Employees: N/A City: MOUNTAIN VIEW
Market Cap: 44.0M IPO Year: 2021
Target Price: $7.50 AVG Volume (30 days): 579.1K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.36 EPS Growth: N/A
52 Week Low/High: $0.75 - $1.69 Next Earning Date: 11-13-2025
Revenue: $662,000 Revenue Growth: N/A
Revenue Growth (this year): 2895.35% Revenue Growth (next year): 313.04%

Stock Insider Trading Activity of RenovoRx Inc. (RNXT)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Bagai Shaun RNXT Chief Executive Officer Aug 25 '25 Buy $0.91 5,000 $4,549.00 330,040
Bagai Shaun RNXT Chief Executive Officer Aug 22 '25 Buy $0.95 5,000 $4,747.50 330,040

Share on Social Networks: